148.54 +0.40 (0.27%)
Pre-market: 6:13AM EST
|Bid||148.95 x 100|
|Ask||149.95 x 100|
|Day's range||146.72 - 148.14|
|52-week range||110.76 - 148.32|
|PE ratio (TTM)||25.76|
|Earnings date||17 Apr 2018|
|Forward dividend & yield||3.36 (2.29%)|
|1y target est||148.50|
Dow components Johnson & Johnson, Verizon and Procter & Gamble report earnings Tuesday, along with hot chipmaker Texas Instruments and United Airlines.
As a bellwether for the industry, Johnson & Johnson’s (JNJ) earnings report tomorrow will be closely watched though most expect a solid quarter. Analysts, on average, expect Johnson & Johnson to report an adjusted fourth quarter profit of $1.72 on revenue of almost $20.1 billion. Here, three observers offer their outlook for Johnson & Johnson: • Allen Bond, co-manager of the Jensen Quality Growth : Bond is looking for three things.
Investors are always looking to find companies that are poised to post better-than-expected earnings results and experience strong post-earnings gains. Today, we are giving our readers a very special treat: a free look at three of the strongest stocks likely to beat earnings estimates this week.
Wynn Resorts, Imax, Johnson & Johnson, Ford and Starbucks as Zacks Bull and Bear of the Day
JNJ stock is currently trading higher than its 50-day moving average of $141.62 and higher than its 200-day moving average of $136.52. Since Johnson & Johnson’s 3Q17 earnings release, JNJ stock has gained ~8.2%. The ongoing restructuring process in its Medical Devices business, new product launches, and its attractive product pipeline are expected by some to further boost investor sentiment and trigger a stock price rise.
Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products.
Alexion, Gilead and Vertex are likely to beat the consensus' fourth-quarter model, an analyst predicted.
Fourth-quarter earnings season is finally underway, and investors are already getting excited about the upcoming reports from market-moving tech companies like Netflix (NFLX). Make sure to keep an eye on these companies as they prepare to report during the week of January 22.
J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.
As we saw in Part 1 of this series, Johnson & Johnson (JNJ) is expected to report a 10.9% growth in revenue to $20.1 billion in 4Q17 compared to 4Q16. The above chart compares the actual revenues for Johnson & Johnson since 1Q16 and estimates for 4Q17. In 4Q17, the segment is expected to report growth in operating revenues, with a favorable impact from foreign exchange.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis